250 related articles for article (PubMed ID: 22998583)
1. Anaplastic lymphoma kinase as a therapeutic target.
Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
Roskoski R
Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
Mesaros EF; Ott GR; Dorsey BD
Expert Opin Ther Pat; 2014 Apr; 24(4):417-42. PubMed ID: 24476492
[TBL] [Abstract][Full Text] [Related]
4. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.
af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J
ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of anaplastic lymphoma kinase: a patent review.
Milkiewicz KL; Ott GR
Expert Opin Ther Pat; 2010 Dec; 20(12):1653-81. PubMed ID: 20961208
[TBL] [Abstract][Full Text] [Related]
8. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
Roskoski R
Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
[TBL] [Abstract][Full Text] [Related]
9. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
10. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase: Role in cancer and therapy perspective.
Zhao Z; Verma V; Zhang M
Cancer Biol Ther; 2015; 16(12):1691-701. PubMed ID: 26529396
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors.
Tothova Z; Wagner AJ
Curr Opin Oncol; 2012 Jul; 24(4):409-13. PubMed ID: 22664824
[TBL] [Abstract][Full Text] [Related]
14. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
15. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
Sakamoto H; Tsukaguchi T; Hiroshima S; Kodama T; Kobayashi T; Fukami TA; Oikawa N; Tsukuda T; Ishii N; Aoki Y
Cancer Cell; 2011 May; 19(5):679-90. PubMed ID: 21575866
[TBL] [Abstract][Full Text] [Related]
16. ALKoma: a cancer subtype with a shared target.
Mano H
Cancer Discov; 2012 Jun; 2(6):495-502. PubMed ID: 22614325
[TBL] [Abstract][Full Text] [Related]
17. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC; McDermott R
Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.
Mossé YP
Clin Cancer Res; 2016 Feb; 22(3):546-52. PubMed ID: 26503946
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.
Kruczynski A; Mayer P; Marchand A; Vispé S; Fournier E; Annereau JP; Brel V; Barret JM; Delsol G; Imbert T; Fahy J; Bailly C
Anticancer Drugs; 2009 Jun; 20(5):364-72. PubMed ID: 19322071
[TBL] [Abstract][Full Text] [Related]
20. Potential therapies for anaplastic lymphoma kinase-driven tumors in children: progress to date.
Lowe EJ; Lim MS
Paediatr Drugs; 2013 Jun; 15(3):163-9. PubMed ID: 23696342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
